Kolexia
Gauthier Helene
Oncologie médicale
Hôpital Saint-Louis
Paris, France
77 Activités
185 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs de la vessie urinaire Métastase tumorale Tumeurs du sein Tumeurs de la prostate Carcinome transitionnel Méningite carcinomateuse Carcinome épidermoïde Néphrocarcinome

Industries

Sanofi
7 collaboration(s)
Dernière en 2021
Ipsen
6 collaboration(s)
Dernière en 2023
Janssen
6 collaboration(s)
Dernière en 2023
Merck-Serono
4 collaboration(s)
Dernière en 2023

Dernières activités

CheckMate358: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors
Essai Clinique (BMS)   08 novembre 2023
MOIO: Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
Essai Clinique (Unicancer)   29 août 2023
Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder cancer in elderly patients.
World journal of urology   09 août 2023
Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
World journal of urology   06 juillet 2023
Preoperative chemotherapy for patients with upper tract urothelial carcinoma: Impact on renal function.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie   04 juillet 2023
Inmunoterapia en urología: principios e indicaciones
EMC - Urología   01 juin 2023
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable): A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Essai Clinique (Bayer)   10 mai 2023
Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series.
Immunotherapy   04 mai 2023
Disseminated Intravascular Coagulation with Enhanced Fibrinolysis Caused by Heart Metastasis of Bladder Urothelial Carcinoma.
Case reports in oncology   30 août 2022
Tratamiento del cáncer de riñón metastásico
EMC - Urología   01 août 2022